Beacon Therapeutics unveils promising interim results for gene therapy AGTC-501

AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316560) and addresses unmet needs within the retinitis space

Feb 28, 2024 - 18:00

Beacon Therapeutics unveils promising interim results for gene therapy AGTC-501

AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316560) and addresses unmet needs within the retinitis space

Read the original article

Tags:

Previous Article

Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease

The importance of high-quality raw materials in the development of Regenerative ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion

STAT+: Novartis to buy German biotech MorphoSys for $2....

Feb 5, 2024

STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs

STAT+: Biotech power broker John Maraganore offers advi...

Oct 18, 2023

STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more

STAT+: Pharmalittle: We’re reading about a nixed Medica...

Mar 4, 2024